Market Overview

UPDATE: Bank Of America Downgrades MedAssets

Related MDAS
Benzinga's Top Upgrades
Leerink Swann Upgrades MedAssets To Outperform

Bank of America downgraded MedAssets (NASDAQ: MDAS) to a Neutral rating upon valuation and assigned a $24 price objective.

Bank of America analyst Robert M. Willoughby said, "The company has benefited from higher demand for its group purchasing and revenue cycle services in the current health care environment, and stronger earnings, coupled with deleveraging in the wake of its Broadlane acquisition in 2010, has pushed ROIC higher at an accelerated clip."

Willoughby continued to cite that MDAS has been trading at an expected P/E multiple of 15.1x for 2015, which is why Willoughby views the stock as fairly valued relative to its historical average of 15.1x.

MedAssets closed Wednesday at $23.41.

Latest Ratings for MDAS

DateFirmActionFromTo
Aug 2014Leerink SwannUpgradesMarket PerformOutperform
Jul 2014Raymond JamesMaintainsOutperform
May 2014CitigroupDowngradesBuyNeutral

View More Analyst Ratings for MDAS
View the Latest Analyst Ratings

Posted-In: Bank of America Robert M. WilloughbyAnalyst Color Downgrades Analyst Ratings

 

Related Articles (MDAS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters